Literature DB >> 11686104

Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function.

D Meyer1, E Fressinaud, L Hilbert, A S Ribba, J M Lavergne, C Mazurier.   

Abstract

Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function comprises mainly subtypes 2A, 2B and 2M. The diagnosis of type 2 von Willebrand disease may be guided by the observation of a disproportionately low level of ristocetin cofactor activity or collagen-binding activity relative to the von Willebrand factor antigen level. The decreased platelet-dependent function is often associated with an absence of high molecular weight multimers (types 2A and 2B), but the high molecular weight multimers may also be present (type 2M and some type 2B), and supranormal multimers may exist (as in the Vicenza variant). Today, the identification of mutations in particular domains of the pre-provon Willebrand factor is helpful to classify these variants and to provide further insight into the structure-function relationship and the biosynthesis of von Willebrand factor. Thus, mutations in the D2 domain, involved in the multimerization process, are found in patients with type 2A, formerly named IIC von Willebrand disease. Mutations in the D3 domain characterize the Vicenza variant, or type IIE patients. Mutations in the A1 domain may modify the binding of von Willebrand factor multimers to platelets, either increasing (type 2B) or decreasing (types 2M and 2A/2M) the affinity of von Willebrand factor for platelets. In type 2A disease, molecular abnormalities identified in the A2 domain, which contains a specific proteolytic site, are associated with alterations in folding that impair the secretion of von Willebrand factor or increase its susceptibility to proteolysis. Finally, a mutation localized in the C terminus cysteine knot domain, which is crucial for the dimerization of von Willebrand factor subunit, has been identified in a rare subtype 2A, formerly named IID.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11686104     DOI: 10.1053/beha.2001.0137

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  4 in total

Review 1.  Acquired Von Willebrand Syndrome (AVWS) in cardiovascular disease: a state of the art review for clinicians.

Authors:  Radha Mehta; Muhammad Athar; Sameh Girgis; Atif Hassan; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2019-07       Impact factor: 2.300

2.  Improving diagnosis of von Willebrand disease: Reference ranges for von Willebrand factor multimer distribution.

Authors:  Inge Vangenechten; Alain Gadisseur
Journal:  Res Pract Thromb Haemost       Date:  2020-07-16

3.  Changes in thermodynamic stability of von Willebrand factor differentially affect the force-dependent binding to platelet GPIbalpha.

Authors:  Matthew Auton; Erik Sedlák; Jozef Marek; Tao Wu; Cheng Zhu; Miguel A Cruz
Journal:  Biophys J       Date:  2009-07-22       Impact factor: 4.033

4.  Antigenic Peptides Capable of Inducing Specific Antibodies for Detection of the Major Alterations Found in Type 2B Von Willebrand Disease.

Authors:  Marina de Oliveira Paro; Cyntia Silva Ferreira; Fernanda Silva Vieira; Marcos Aurélio de Santana; William Castro-Borges; Maria Sueli Silva Namen-Lopes; Sophie Yvette Leclercq; Cibele Velloso-Rodrigues; Milton Hércules Guerra de Andrade
Journal:  Int J Pept       Date:  2013-07-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.